Clostridium difficile is the leading cause of hospital-acquired diarrhea, known as C. difficile-associated disease. The estimated number of cases of C. difficile-associated disease exceeds 250,000 per year (1), with health care costs approaching US $1 billion annually (2). The major virulence factors produced by C. difficile are two toxins, TcdA and TcdB. Both toxins can monoglucosylate and inactivate Rho family small GTPases within target cells, leading to disruption of vital signaling pathways in the cell, subsequently causing diarrhea, inflammation, and damage of colonic mucosa (3, 4, 5). Both toxins have a similar tripartite structure comprised of an N‑terminal glucosyltransferase domain, a C-terminal receptor binding domain, and a small hydrophobic span possibly involved in toxin translocation (6). Our recombinant TcdB consists of the enzymatic domain. Both TcdA and TcdB also have potassium-dependent UDP-Glc hydrolase activity, which is essentially glucosyltransferase activity with water as the acceptor molecule (7). Under same conditions, UDP-glucose hydrolysis by TcdB occurs at a rate about 5-fold greater than that of TcdA.
C. difficile Toxin B/TcdB Antibody
R&D Systems | Catalog # AF6246
Key Product Details
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Ser2-Leu543
Accession # P18177
Specificity
Clonality
Host
Isotype
Scientific Data Images for C. difficile Toxin B/TcdB Antibody
Detection ofC. difficileToxin B/TcdB by Western Blot.
Western blot shows recombinantC. difficileToxin B/TcdB (Catalog # 6246-GT). PVDF membrane was probed with 1 µg/mL of Sheep Anti-C. difficileToxin B/TcdB Antigen Affinity-purified Polyclonal Antibody (Catalog # AF6246) followed by HRP-conjugated Anti-Sheep IgG Secondary Antibody (Catalog # HAF016). A specific band was detected for Toxin B/TcdB at approximately 75 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
Detection of C. difficile Toxin B/TcdB by Western Blot
Effective TcdB cell interactions correlate with endocytosis. (A, B) Representative confocal maximum-intensity projections of CHO-K1 cells stained with 250 nM Alexa Fluor 647-labeled TcdB1 B2′B3 (red) (A) or Alexa Fluor 647-labeled TcdB2 B2′B3 (red) (B). Ten micromolar calcein AM (green) was used to counterstain the cytoplasm of live cells with intact membranes, and 0.5 μg/ml Hoechst 33258 (blue) was used to visualize the nucleus. (C) Quantification of the images in panels A and B, expressed as corrected total cell fluorescence. (D) Representative immunoblotting of full-length TcdB1 and TcdB2 associated with CHO-K1 cells in the presence or absence the dynamin inhibitor dynasore (80 μM). Incubations were carried out for 30 min at 37°C. (E) Quantification of data presented in panel D, expressed as relative band density. (F) Representative immunoblotting of full-length TcdB1 and TcdB2 associated with CHO-K1 cells when incubations were carried out for 30 min at a temperature that permits (37°C) or inhibits (ice) endocytosis. (G) Quantification of data presented in panel F, expressed as relative band density. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28776043), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of C. difficile Toxin B/TcdB by Western Blot
Mechanism-of-action of niclosamide inhibition of TcdB intoxication. c In vitro auto-processing assay. Compound or DMSO was added to 100 nM TcdB, and pre-incubated for 60 min. To initiate auto-processing, InsP6 was added (100 μM) and incubated @ 37 °C for 20 min before stopping with Laemlii sample buffer. Niclosamide at concentrations up to 10 μM did not affect auto-processing (n = 2). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30531960), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of C. difficile Toxin B/TcdB by Western Blot
Impact of PepB2 on TcdB enzymatic activity, thermal stability, and cell association. (G) Immunoblot analysis of TcdB associating with cells for 30 min. CHO-K1 cells were exposed at 37°C to 4 nM TcdB in the presence and absence of 50 µM peptide. The cells were then washed, and total cell lysates were examined by immunoblotting. In this figure, all bar graphs represent the mean densitometry value ± standard deviation, and asterisks indicate significant change. *, P < 0.01; **, P < 0.001. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28512094), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of C. difficile Toxin B/TcdB by Western Blot
Mechanism-of-action of niclosamide inhibition of TcdB intoxication. a Western blot image for intracellular Rac1 glucosylation (n = 3). IMR-90 cells were treated with niclosamide (doses indicated) for 15 min, followed by treatment with 0.5 pM TcdB. Cells were harvested as described in Methods. Mab102, which recognizes un-glucosylated Rac1 in cells, shows a dose-dependent re-appearance with increasing concentration of niclosamide, relative to total Rac1 levels (n = 2). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30531960), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for C. difficile Toxin B/TcdB Antibody
Western Blot
Sample: Recombinant C. difficile Toxin B/TcdB (Catalog # 6246-GT)
Formulation, Preparation, and Storage
Purification
Reconstitution
Sterile PBS to a final concentration of 0.2 mg/mL. For liquid material, refer to CoA for concentration.
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: Toxin B/TcdB
References
- Wilkins, T.D. and Lyerly, D.M. (2003) J. Clin. Microbiol 41:53.
- Kyne, L. et al. (2002) Clin. Infect. Dis. 34:346.
- Voth, D.E. and Ballard, J.D. (2005) Clin. Microbiol. Rev. 18:247.
- Chaves-Olarte, E. et al. (1996) J. Biol. Chem. 271:6925.
- Just I, et al. (1995) J. Biol. Chem. 270:13932.
- Hammond, G.A. and Johnson, J.L. (1995) Microb. Pathog. 19:203.
- Ciesla, W.P. Jr. and Bobak, D.A. (1998) J. Biol. Chem. 273:16021.
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional Toxin B/TcdB Products
Product Documents for C. difficile Toxin B/TcdB Antibody
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for C. difficile Toxin B/TcdB Antibody
For research use only
Related Research Areas
Citations for C. difficile Toxin B/TcdB Antibody
Customer Reviews for C. difficile Toxin B/TcdB Antibody
There are currently no reviews for this product. Be the first to review C. difficile Toxin B/TcdB Antibody and earn rewards!
Have you used C. difficile Toxin B/TcdB Antibody?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- Cellular Response to Hypoxia Protocols
- R&D Systems Quality Control Western Blot Protocol
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars